Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling.
Androgen Antagonists
/ pharmacology
Animals
Cation Transport Proteins
/ genetics
Cell Line, Tumor
Cell Membrane
/ metabolism
Cell Movement
Cystectomy
Datasets as Topic
Dihydrotestosterone
/ metabolism
Disease Progression
Female
GTP-Binding Protein alpha Subunits, Gi-Go
/ antagonists & inhibitors
Humans
Indazoles
/ pharmacology
MAP Kinase Signaling System
/ drug effects
Male
Matrix Metalloproteinase 9
/ metabolism
Mice
Middle Aged
Neoplasm Invasiveness
/ pathology
Pertussis Toxin
/ pharmacology
Piperazines
/ pharmacology
Prognosis
RNA, Small Interfering
/ metabolism
Urinary Bladder
/ cytology
Urinary Bladder Neoplasms
/ mortality
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
22
12
2018
accepted:
15
05
2019
revised:
08
05
2019
pubmed:
12
9
2019
medline:
20
6
2020
entrez:
12
9
2019
Statut:
ppublish
Résumé
While androgens may function via nuclear androgen receptor (nAR) to increase bladder cancer (BCa) progression, the impact of androgens on muscle invasive BCa, which contains nearly 80% nAR-negative cells, remains unclear. To dissect the androgens potential impacts on these nAR-negative muscle invasive BCa, we first found that the androgens, dihydrotestosterone (DHT) might function via a novel membrane AR (mAR-SLC39A9) to increase nAR-negative BCa cell migration and invasion. Mechanism dissection revealed that DHT/mAR-SLC39A9 might function by altering G
Identifiants
pubmed: 31506605
doi: 10.1038/s41388-019-0964-6
pii: 10.1038/s41388-019-0964-6
doi:
Substances chimiques
Androgen Antagonists
0
Cation Transport Proteins
0
Indazoles
0
Piperazines
0
RNA, Small Interfering
0
SCH772984
0
Slc39a9 protein, human
0
Dihydrotestosterone
08J2K08A3Y
Pertussis Toxin
EC 2.4.2.31
MMP9 protein, human
EC 3.4.24.35
Matrix Metalloproteinase 9
EC 3.4.24.35
GTP-Binding Protein alpha Subunits, Gi-Go
EC 3.6.5.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
574-586Références
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108.
doi: 10.1016/j.eururo.2016.06.010
pubmed: 27370177
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
pubmed: 28055103
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796–810.
doi: 10.1016/S0140-6736(16)30512-8
pubmed: 27345655
Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22–31.
doi: 10.1016/j.ctrv.2016.05.002
pubmed: 27231966
Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34:1945–52.
doi: 10.1200/JCO.2015.65.9797
pubmed: 27001593
Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 2015;41:170–8.
doi: 10.1016/j.ctrv.2014.11.003
pubmed: 25498841
Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69:300–10.
doi: 10.1016/j.eururo.2015.08.037
pubmed: 26346676
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.
doi: 10.3322/caac.20121
pubmed: 21685461
Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33:3225–34.
doi: 10.1038/onc.2013.274
pubmed: 23873027
Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 1988;240:324–6.
doi: 10.1126/science.3353726
pubmed: 3353726
Li P, Chen J, Miyamoto H. Androgen receptor signaling in bladder cancer. Cancers (Basel). 2017;9:E20.
doi: 10.3390/cancers9020020
Miyamoto H, Zheng Y, Izumi K. Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Targets. 2012;12:14–22.
doi: 10.2174/156800912798888965
pubmed: 22111835
Ou Z, Wang Y, Liu L, Li L, Yeh S, Qi L, et al. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. Oncotarget. 2015;6:26065–78.
pubmed: 26305549
pmcid: 4694886
Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol. 2011;29:43–51.
doi: 10.1016/j.urolonc.2009.01.033
pubmed: 19372057
Ide H, Inoue S, Miyamoto H. Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies. PLoS ONE. 2017;12:e0174746.
doi: 10.1371/journal.pone.0174746
pubmed: 28362839
pmcid: 5375178
Sun YH, Gao X, Tang YJ, Xu CL, Wang LH. Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. J Androl. 2006;27:671–8.
doi: 10.2164/jandrol.106.000554
pubmed: 16728719
Sen A, Prizant H, Hammes SR. Understanding extranuclear (nongenomic) androgen signaling: what a frog oocyte can tell us about human biology. Steroids. 2011;76:822–8.
pubmed: 21354434
pmcid: 4972037
Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocr. 2008;29:169–81.
doi: 10.1016/j.yfrne.2007.10.005
Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99:558–68.
doi: 10.1093/jnci/djk113
pubmed: 17406000
De Toni L, Guidolin D, De Filippis V, Tescari S, Strapazzon G, Santa Rocca M, et al. Osteocalcin and sex hormone binding globulin compete on a specific binding site of GPRC6A. Endocrinology. 2016;157:4473–86.
doi: 10.1210/en.2016-1312
pubmed: 27673554
Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010;285:39953–64.
doi: 10.1074/jbc.M110.158063
pubmed: 20947496
pmcid: 3000977
Thomas P, Pang Y, Dong J, Berg AH. Identification and characterization of membrane androgen receptors in the ZIP9 zinc transporter subfamily: II. Role of human ZIP9 in testosterone-induced prostate and breast cancer cell apoptosis. Endocrinology. 2014;155:4250–65.
doi: 10.1210/en.2014-1201
pubmed: 25014355
pmcid: 4197988
Thomas P, Pang Y, Dong J. Membrane androgen receptor characteristics of human ZIP9 (SLC39A) zinc transporter in prostate cancer cells: androgen-specific activation and involvement of an inhibitory G protein in zinc and MAP kinase signaling. Mol Cell Endocrinol. 2017;447:23–34.
doi: 10.1016/j.mce.2017.02.025
pubmed: 28219737
Munnich N, Wernhart S, Hogstrand C, Schlomann U, Nimsky C, Bartsch JW. Expression of the zinc importer protein ZIP9/SLC39A9 in glioblastoma cells affects phosphorylation states of p53 and GSK-3beta and causes increased cell migration. Biometals. 2016;29:995–1004.
doi: 10.1007/s10534-016-9971-z
pubmed: 27654922
Thal DM, Glukhova A, Sexton PM, Christopoulos A. Structural insights into G-protein-coupled receptor allostery. Nature. 2018;559:45–53.
doi: 10.1038/s41586-018-0259-z
pubmed: 29973731
Tang X, Jin R, Qu G, Wang X, Li Z, Yuan Z, et al. GPR116, an adhesion G-protein-coupled receptor, promotes breast cancer metastasis via the Galphaq-p63RhoGEF-Rho GTPase pathway. Cancer Res. 2013;73:6206–18.
doi: 10.1158/0008-5472.CAN-13-1049
pubmed: 24008316
Gao ZG, Jacobson KA. On the selectivity of the Galphaq inhibitor UBO-QIC: a comparison with the Galphai inhibitor pertussis toxin. Biochem Pharm. 2016;107:59–66.
doi: 10.1016/j.bcp.2016.03.003
pubmed: 26954502
Berg AH, Rice CD, Rahman MS, Dong J, Thomas P. Identification and characterization of membrane androgen receptors in the ZIP9 zinc transporter subfamily: I. Discovery in female atlantic croaker and evidence ZIP9 mediates testosterone-induced apoptosis of ovarian follicle cells. Endocrinology. 2014;155:4237–49.
doi: 10.1210/en.2014-1198
pubmed: 25014354
pmcid: 4197986
Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA. 2008;105:12182–7.
doi: 10.1073/pnas.0804700105
pubmed: 18723679
pmcid: 2527886
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308.
doi: 10.1210/er.2002-0032
pubmed: 15082523
Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. Steroids. 1999;64:100–6.
doi: 10.1016/S0039-128X(98)00108-1
pubmed: 10323678
Lieberherr M, Grosse B. Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem. 1994;269:7217–23.
pubmed: 8125934
Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate. 2012;72:399–409.
doi: 10.1002/pros.21442
pubmed: 21681779
Thomas P, Converse A, Berg HA. ZIP9, a novel membrane androgen receptor and zinc transporter protein. Gen Comp Endocrinol. 2018;257:130–6.
doi: 10.1016/j.ygcen.2017.04.016
pubmed: 28479083
Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget. 2014;5:12665–74.
doi: 10.18632/oncotarget.2851
pubmed: 25557268
pmcid: 4350350
Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, et al. Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. Oncotarget. 2015;6:14710–9.
pubmed: 25900243
pmcid: 4546499
Goldsmith ZG, Dhanasekaran DN. G protein regulation of MAPK networks. Oncogene. 2007;26:3122–42.
doi: 10.1038/sj.onc.1210407
pubmed: 17496911
Wang JL, Yang MY, Xiao S, Sun B, Li YM, Yang LY. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling. J Exp Clin Cancer Res. 2018;37:45.
doi: 10.1186/s13046-018-0720-8
pubmed: 29506567
pmcid: 5836448
Huang B, Xiao E, Huang M. MEK/ERK pathway is positively involved in hypoxia-induced vasculogenic mimicry formation in hepatocellular carcinoma which is regulated negatively by protein kinase A. Med Oncol. 2015;32:408.
doi: 10.1007/s12032-014-0408-7
pubmed: 25487444
Liu Q, Zou R, Zhou R, Gong C, Wang Z, Cai T, et al. miR-155 regulates glioma cells invasion and chemosensitivity by p38 isforms in vitro. J Cell Biochem. 2015;116:1213–21.
doi: 10.1002/jcb.25073
pubmed: 25535908